Related Experiment Video
Updated: Jul 11, 2026
07:39
Corneal and Limbal Alkali Injury Induction Using a Punch-Trephine Technique in a Mouse Model
Published on: August 4, 2023
[Persistent corneal defects treated with botulinum toxin-induced ptosis]
E N Vleming1, C Pérez-Rico, M A Montes
1Servicio de Oftalmología del Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain. e_vleming@yahoo.es
Archivos De La Sociedad Espanola De Oftalmologia
|September 12, 2007
Summary
Botulinum toxin (BTX) injections successfully treated refractory corneal pathology by inducing ptosis, leading to lesion resolution in all cases. This safe and simple method offers advantages over surgical tarsorrhaphy for non-surgical corneal conditions.
Area of Science:
- Ophthalmology
- Neuromodulation
- Corneal Disease Treatment
Context:
- Refractory corneal pathologies present significant treatment challenges.
- Traditional surgical interventions like tarsorrhaphy carry risks and may not be suitable for all cases.
- Botulinum toxin (BTX) offers a potential non-surgical therapeutic approach.
Purpose:
- To evaluate the efficacy and safety of using botulinum toxin (BTX)-induced ptosis for treating corneal pathology.
- To compare BTX treatment with existing surgical methods.
Summary:
- Botulinum toxin (BTX) was administered via injections to induce ptosis in 10 eyes across 9 patients with corneal pathology.
- Complete ptosis was achieved in seven eyes, resulting in the complete resolution of corneal lesions.
- No significant complications were reported during the study period.
Impact:
- Botulinum toxin (BTX) provides a simple, safe, and effective non-surgical treatment option for refractory corneal pathologies.
- This method demonstrates significant advantages over surgical tarsorrhaphy, particularly for corneal conditions not necessitating surgical intervention.
- BTX-induced ptosis represents a valuable therapeutic strategy in ophthalmology.
